Stocktoria
Lexaria Bioscience Corp. LEXX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2009-10-28
Lexaria Bioscience Corp. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | 99.6% | 99.0% | 86.1% | 71.9% | 75.7% |
| Operating margin | -1683.0% | -1239.2% | -2888.5% | -2591.7% | -786.8% |
| Net margin | -1686.0% | -1248.2% | -2946.4% | -2846.3% | -557.2% |
| FCF margin | -1483.9% | -1077.4% | -2614.8% | -1929.8% | — |
| Return on assets | -285.1% | -65.4% | -216.1% | -92.8% | -30.4% |
| Return on equity | -398.1% | -72.1% | -218.9% | -91.5% | -30.8% |
| Current ratio | 2.32 | 7.18 | 8.03 | 35.96 | 81.18 |
| Revenue growth | 52.0% | 105.2% | -11.4% | -64.7% | 87.9% |
Source: SEC EDGAR filings · CIK 0001348362 · as of 2025-08-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.